The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells
Open accessAbstract
We performed a phase 1 clinical trial to evaluate outcomes in patients receiving donor-derived CD19-specific chimeric antigen receptor (CAR) T cells for B-cell malignancy that relapsed or persisted after matched related allogeneic hemopoietic stem cell transplant. To overcome the cost and transgene-capacity limitations of traditional viral vectors, CAR T cells were produced using the piggyBac transposon system of genetic modification. Following CAR T-cell infusion, 1 patient developed a gradually enlarging retroperitoneal tumor due to a CAR-expressing CD4+ T-cell lymphoma. Screening of other patients led to the detection, in an asymptomatic patient, of a second CAR T-cell tumor in thoracic para-aortic lymph nodes. Analysis of the first lymphoma showed a high transgene copy number, but no insertion into typical oncogenes. There were also structural changes such as altered genomic copy number and point mutations unrelated to the insertion sites. Transcriptome analysis showed transgene promoter–driven upregulation of transcription of surrounding regions despite insulator sequences surrounding the transgene. However, marked global changes in transcription predominantly correlated with gene copy number rather than insertion sites. In both patients, the CAR T-cell–derived lymphoma progressed and 1 patient died. We describe the first 2 cases of malignant lymphoma derived from CAR gene–modified T cells. Although CAR T cells have an enviable record of safety to date, our results emphasize the need for caution and regular follow-up of CAR T recipients, especially when novel methods of gene transfer are used to create genetically modified immune therapies. This trial was registered at www.anzctr.org.au as ACTRN12617001579381.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, in a recent phase I trial, lymphoma arising from piggyBac transfected CAR T cells has been reported in two of nine patients with relapsed or refractory B-cell malignancies who achieved complete remission after product infusion.”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [108]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Self-citationDisruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862
Structural variant calling: the long and the short of it
Mahmoud, M., Gobet, N., Cruz-Dávalos, D. I., Mounier, N., Dessimoz, C., & Sedlazeck, F. J. (2019) · Genome Biology · doi:10.1186/s13059-019-1828-7 · Cited by 725
Self-citationBishop, D. C., Clancy, L. E., Simms, R., Burgess, J., Mathew, G., Moezzi, L., Street, J. A., Sutrave, G., Atkins, E., McGuire, H. M., et al. (2021) · Blood · doi:10.1182/blood.2021010813 · Cited by 177
Self-citation
Research works printed but not linked: 62
- Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med., 377, 2531, 10.1056/NEJMoa1707447 · DOI · Paper page
- Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science., 302, 415, 10.1126/science.1088547 · DOI · Paper page
- Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J Clin Invest., 118, 3143, 10.1172/JCI35798 · DOI · Paper page
- Shah, 2019, Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy, Blood Adv., 3, 2317, 10.1182/bloodadvances.2019000219 · DOI
- Newrzela, 2011, Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes, Mol Med., 17, 1223, 10.2119/molmed.2010.00193 · DOI
- Kebriaei, 2016, Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells, J Clin Invest., 126, 3363, 10.1172/JCI86721 · DOI
- Manuri, 2010, piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies, Hum Gene Ther., 21, 427, 10.1089/hum.2009.114 · DOI
- Morita, 2017, Enhanced expression of anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells, Mol Ther Methods Clin Dev., 8, 131, 10.1016/j.omtm.2017.12.003 · DOI
- Saha, 2012, piggyBac transposon system modification of primary human T cells, J Vis Exp., e4235
- Ramanayake, 2015, Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials, Cytotherapy., 17, 1251, 10.1016/j.jcyt.2015.05.013 · DOI
- Bishop, 2018, PiggyBac-engineered T cells expressing CD19-specific CARs that lack IgG1 Fc spacers have potent activity against B-ALL xenografts, Mol Ther., 26, 1883, 10.1016/j.ymthe.2018.05.007 · DOI
- Singh, 2013, Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells, PLoS One., 8, e64138, 10.1371/journal.pone.0064138 · DOI
- Ryland, 2018, Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing, J Clin Pathol., 71, 895, 10.1136/jclinpath-2018-205195 · DOI
- Markham, 2019, CNspector: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing, Sci Rep., 9, 6426, 10.1038/s41598-019-42858-8 · DOI
- Brady, 2011, A method to sequence and quantify DNA integration for monitoring outcome in gene therapy, Nucleic Acids Res., 39, e72, 10.1093/nar/gkr140 · DOI
- Kamboj, 2017, Ub-ISAP: a streamlined UNIX pipeline for mining unique viral vector integration sites from next generation sequencing data, BMC Bioinformatics., 18, 305, 10.1186/s12859-017-1719-4 · DOI
- Freed, The Sentieon Genomics Tools - a fast and accurate solution to variant calling from next-generation sequence data, 10.1101/115717 · DOI
- Jeffares, 2017, Transient structural variations have strong effects on quantitative traits and reproductive isolation in fission yeast, Nat Commun., 8, 14061, 10.1038/ncomms14061 · DOI
- Dennenmoser, 2019, Genome-wide patterns of transposon proliferation in an evolutionary young hybrid fish, Mol Ecol., 28, 1491, 10.1111/mec.14969 · DOI
- Rausch, 2012, DELLY: structural variant discovery by integrated paired-end and split-read analysis, Bioinformatics., 28, i333, 10.1093/bioinformatics/bts378 · DOI
- Layer, 2014, LUMPY: a probabilistic framework for structural variant discovery, Genome Biol., 15, R84, 10.1186/gb-2014-15-6-r84 · DOI
- Chen, 2016, Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications, Bioinformatics., 32, 1220, 10.1093/bioinformatics/btv710 · DOI
- Heinz, 2010, Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities, Mol Cell., 38, 576, 10.1016/j.molcel.2010.05.004 · DOI · Paper page
- Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics., 29, 15, 10.1093/bioinformatics/bts635 · DOI · Paper page
- Robinson, 2011, Integrative genomics viewer, Nat Biotechnol., 29, 24, 10.1038/nbt.1754 · DOI · Paper page
- Lawrence, 2013, Software for computing and annotating genomic ranges, PLOS Comput Biol., 9, e1003118, 10.1371/journal.pcbi.1003118 · DOI
- Lawrence, 2009, rtracklayer: an R package for interfacing with genome browsers, Bioinformatics., 25, 1841, 10.1093/bioinformatics/btp328 · DOI
- Yu, 2012, clusterProfiler: an R package for comparing biological themes among gene clusters, OMICS., 16, 284, 10.1089/omi.2011.0118 · DOI · Paper page
- Shugay, 2018, VDJdb: a curated database of T-cell receptor sequences with known antigen specificity, Nucleic Acids Res., 46, D419, 10.1093/nar/gkx760 · DOI
- Salter, 2018, Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function, Sci Signal., 11, eaat6753, 10.1126/scisignal.aat6753 · DOI
- Tate, 2019, COSMIC: the Catalogue Of Somatic Mutations In Cancer, Nucleic Acids Res., 47, D941, 10.1093/nar/gky1015 · DOI · Paper page
- Galvan, 2009, Genome-wide mapping of PiggyBac transposon integrations in primary human T cells, J Immunother., 32, 837, 10.1097/CJI.0b013e3181b2914c · DOI
- Hamada, 2018, Integration mapping of piggyBac-mediated CD19 chimeric antigen receptor T cells analyzed by novel tagmentation-assisted PCR, EBioMedicine., 34, 18, 10.1016/j.ebiom.2018.07.008 · DOI
- Li, 2013, A resurrected mammalian hAT transposable element and a closely related insect element are highly active in human cell culture, Proc Natl Acad Sci USA., 110, E478, 10.1073/pnas.1121543109 · DOI
- Aganezov, 2020, Comprehensive analysis of structural variants in breast cancer genomes using single-molecule sequencing, Genome Res., 30, 1258, 10.1101/gr.260497.119 · DOI
- Sedlazeck, 2018, Accurate detection of complex structural variations using single-molecule sequencing, Nat Methods., 15, 461, 10.1038/s41592-018-0001-7 · DOI
- Chung, 1997, Characterization of the chicken beta-globin insulator, Proc Natl Acad Sci USA., 94, 575, 10.1073/pnas.94.2.575 · DOI
- Sugie, 2004, Activation of naïve CD4 T cells by anti-CD3 reveals an important role for Fyn in Lck-mediated signaling, Proc Natl Acad Sci USA., 101, 14859, 10.1073/pnas.0406168101 · DOI
- Kataoka, 2015, Integrated molecular analysis of adult T cell leukemia/lymphoma, Nat Genet., 47, 1304, 10.1038/ng.3415 · DOI
- Muragaki, 1991, The complete primary structure of the human alpha 1 (VIII) chain and assignment of its gene (COL8A1) to chromosome 3, Eur J Biochem., 197, 615, 10.1111/j.1432-1033.1991.tb15951.x · DOI
- Liu, 2018, Identification of potential key genes associated with the pathogenesis and prognosis of gastric cancer based on integrated bioinformatics analysis, Front Genet., 9, 265, 10.3389/fgene.2018.00265 · DOI
- Patsoukis, 2020, Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation, Commun Biol., 3, 128, 10.1038/s42003-020-0845-0 · DOI · Paper page
- Richer, 2016, T cell fates zipped up: how the Bach2 basic leucine zipper transcriptional repressor directs T cell differentiation and function, J Immunol., 197, 1009, 10.4049/jimmunol.1600847 · DOI
- Sakane-Ishikawa, 2005, Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group, J Clin Oncol., 23, 8012, 10.1200/JCO.2005.02.1626 · DOI
- Ichikawa, 2014, Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma, Cancer Sci., 105, 437, 10.1111/cas.12361 · DOI
- Liu, 2009, Identification of novel Bach2 transcripts and protein isoforms through tagging analysis of retroviral integrations in B-cell lymphomas, BMC Mol Biol., 10, 2, 10.1186/1471-2199-10-2 · DOI
- Ikeda, 2007, Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy, J Infect Dis., 195, 716, 10.1086/510915 · DOI
- Cesana, 2017, HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells, Nat Commun., 8, 498, 10.1038/s41467-017-00609-1 · DOI
- Newrzela, 2012, T-cell receptor diversity prevents T-cell lymphoma development, Leukemia., 26, 2499, 10.1038/leu.2012.142 · DOI
- Scholler, 2012, Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells, Sci Transl Med., 4, 132ra53, 10.1126/scitranslmed.3003761 · DOI
- Recchia, 2006, Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells, Proc Natl Acad Sci USA., 103, 1457, 10.1073/pnas.0507496103 · DOI
- Sheih, 2020, Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy, Nat Commun., 11, 219, 10.1038/s41467-019-13880-1 · DOI
- Nakazawa, 2013, Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes, J Immunother., 36, 3, 10.1097/CJI.0b013e3182791234 · DOI
- Nakazawa, 2011, PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor, Mol Ther., 19, 2133, 10.1038/mt.2011.131 · DOI
- Saito, 2014, Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia, Cytotherapy., 16, 1257, 10.1016/j.jcyt.2014.05.022 · DOI
- Gregory, 2018, Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM), Blood., 132, 1012, 10.1182/blood-2018-99-111419 · DOI
- Costello, 2019, Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM) (PRIME), Blood., 134, 3184, 10.1182/blood-2019-129562 · DOI
- Ramezani, 2003, Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator, Blood., 101, 4717, 10.1182/blood-2002-09-2991 · DOI
- Arumugam, 2009, Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region, Mol Ther., 17, 1929, 10.1038/mt.2009.183 · DOI
- Grosso, 2015, Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma, eLife., 4, e09214, 10.7554/eLife.09214 · DOI · Paper page
- Ambrosini, 2018, PWMScan: a fast tool for scanning entire genomes with a position-specific weight matrix, Bioinformatics., 34, 2483, 10.1093/bioinformatics/bty127 · DOI
- Gu, 2014, circlize implements and enhances circular visualization in R, Bioinformatics., 30, 2811, 10.1093/bioinformatics/btu393 · DOI
Cited by
Sorted by citations
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 810
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 695
From bench to bedside: the history and progress of CAR T cell therapy
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q. F., & He, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188049 · Cited by 526
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0084 · Cited by 321
“The analysis of the lymphoma samples showed an increase in the transgene copy numbers but with no integration in typical oncogenes (107, 108).”
BackgroundCAR-T cell manufacturing: Major process parameters and next-generation strategies
Ceja, M. A., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230903 · Cited by 349
“Post-hoc analysis indicated that the malignant CAR-T cells did not contain transgene insertion into known oncogenic sites but displayed significant copy-number gains and losses of multiple chromosomes as well as transcriptional readthrough from the transgene promoter (Micklethwaite et al., 2021).”
BackgroundCurrent understanding and management of CAR T cell-associated toxicities
Brudno, J. N., & Kochenderfer, J. N. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00903-0 · Cited by 352
“…cell-derived malignancies, CAR + T cell lymphoma occurred in two patients who received investigational allogeneic, donor-derived CD19-directed CAR T cells genetically modified using a PiggyBac transposon system; however, no integration of the transgene into known oncogenes was identified 151,152 .”
Chen, S., Zhu, H., & Jounaïdi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02005-w · Cited by 283
“Given recent reports of CAR-T lymphoma risks, 641 this approach could also test the safety of new immunotherapies due to potential risks associated with gene editing strategies, with possible off-target effects, which might also be seen in CAR-NK therapies if used at larger scales.”
BackgroundBase-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia
Chiesa, R., Georgiadis, C., Syed, F., Zhan, H., Etuk, A., Gkazi, S. A., Preece, R., Ottaviano, G., Braybrook, T., Chu, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300709 · Cited by 353
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Ghilardi, G., Fraietta, J., Gerson, J., Deerlin, V. V., Morrissette, J. J. D., Caponetti, G. C., Paruzzo, L., Harris, J., Chong, E. A., Susanibar-Adaniya, S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02826-w · Cited by 249
“Other than in the cases treated with the piggy-Bac transposon-engineered CAR T cells 20 , none of the previously discussed SPMs was directly caused by CAR transduction; however, a case of CAR + TCL occurring after infusion of the BCMA-directed CAR T (CART-BCMA) ciltacabtagene autoleucel…”
Engineered cellular immunotherapies in cancer and beyond
Finck, A., Blanchard, T., Roselle, C., Golinelli, G., & June, C. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 277
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
Levine, B. L., Pasquini, M., Connolly, J. E., Porter, D. L., Gustafson, M. P., Boelens, J., Horwitz, E. M., Grupp, S., Maus, M. V., Locke, F., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02767-w · Cited by 190
Shy, B. R., Vykunta, V. S., Ha, A. S., Talbot, A., Roth, T. L., Nguyen, D. N., Pfeifer, W. G., Chen, Y. Y., Blaeschke, F., Shifrut, E., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01418-8 · Cited by 223
Bishop, D. C., Clancy, L. E., Simms, R., Burgess, J., Mathew, G., Moezzi, L., Street, J. A., Sutrave, G., Atkins, E., McGuire, H. M., et al. (2021) · Blood · doi:10.1182/blood.2021010813 · Cited by 177
Self-citationOttaviano, G., Georgiadis, C., Gkazi, S. A., Syed, F., Zhan, H., Etuk, A., Preece, R., Chu, J., Kubat, A., Adams, S. P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq3010 · Cited by 212
Kok, N., Panella, D., Georgoudaki, A., Liu, H., Özkazanç, D., Kučerová, L., Duru, A. D., Spanholtz, J., & Raimo, M. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01382-5 · Cited by 191
“Transposons have been used in CAR-T setting [159, 160]; however, CAR-T cell lymphoma was developed by patients treated with piggyBac-modified cells [160], possibly related to insertional oncogenesis, where a high vector copy number was found in one of such patients [161].”
The Past, Present, and Future of Non-Viral CAR T Cells
Moretti, A., Ponzo, M., Nicolette, C. A., Tcherepanova, I. Y., Biondi, A., & Magnani, C. F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867013 · Cited by 167
T cell dysfunction and therapeutic intervention in cancer
Zebley, C. C., Zehn, D., Gottschalk, S. M., & Chi, H. (2024) · Nature Immunology · doi:10.1038/s41590-024-01896-9 · Cited by 145
“However, rare genetic modifications that contribute to CAR T cell malignancies have been reported 162,163 .”
Direct in vivo CAR T cell engineering
Short, L., Holt, R. A., Cullis, P. R., & Evgin, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.03.004 · Cited by 141
“DNA plasmids encoding the CAR fl anked by ITRs and the PiggyBac transposase to generate a population of CAR T cells [26] should be approached with caution as a small fraction of CAR T cells manufactured ex vivo using a similar approach has been reported to lead to T cell lymphomas [52].”
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
Michels, A., Ho, N., & Buchholz, C. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.018 · Cited by 131
“In contrast to LVs, transposonmediated gene transfer had its “SCID moment” last year, when two patients receiving CAR T cells generated ex vivo using piggyBac transposase developed T cell lymphoma.(107,108) Although themechanism of oncogenesis is still under investigation, this incident must lead to development of saf…”
EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors
Li, D., Guo, X., Yang, K., Yang, Y., Zhou, W., Huang, Y., Liang, X., Su, J., Jiang, L., Li, J., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg9721 · Cited by 97
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies
Jadlowsky, J. K., Hexner, E. O., Marshall, A., Grupp, S. A., Frey, N. V., Riley, J. L., Veloso, E. A., McConville, H., Rogal, W., Czuczman, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03478-6 · Cited by 91
“In contrast, a study using the piggyBac transposon system to deliver a CAR transgene found that two of ten patients developed lymphoma with malignant T cells marked by transposon DNA 36 .”
Irving, M. B., Lanitis, E., Migliorini, D., Ivics, Z., & Guedan, S. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.173 · Cited by 112
“Following CAR-T cell infusion, two patients developed T cell lymphoma leading to the death of one of the patients.(49,50)”
BackgroundCD4+ T cell lymphoma harboring a chimeric antigen receptor integration in TP53
Perica, K., Jain, N., Scordo, M., Patel, R., Eren, O., Patel, U., Gundem, G., Domenico, D., Mitra, S., Socci, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2411507 · Cited by 82
Li, S., Ling, S., Wang, D., Wang, X., Hao, F., Yin, L., Yuan, Z., Liu, L., Zhang, L., Li, Y., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.04.021 · Cited by 87
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy.
Ozdemirli, M., Loughney, T. M., Deniz, E., Chahine, J., Albitar, M., Pittaluga, S., Sadigh, S., Armand, P., Üren, A., & Anderson, K. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401530 · Cited by 80
Du, Z., Ng, Y., Zha, S., & Wang, S. (2021) · Molecular Therapy: Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.014 · Cited by 79
“The authors further confirmed that marked global changes in transcriptionmainly correlated with a high transgene copy number per cell rather than insertion sites.(69) A significantly higher VCN suggests that CAR overexpression could have contributed to a survival advantage of individual PB CAR-T cell clones, especiall…”
BackgroundResultInfluentialPromises and challenges of a decentralized CAR T-cell manufacturing model
Shah, M., Krull, A., Odonnell, L., de Lima, M. J., & Bezerra, E. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1238535 · Cited by 77
Cell and gene therapy for kidney disease
Peek, J. L., & Wilson, M. H. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00702-3 · Cited by 86
Tipanee, J., Samara-Kuko, E., Gevaert, T., Chuah, M. K., & VandenDriessche, T. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.006 · Cited by 76
Non-viral chimeric antigen receptor (CAR) T cells going viral
Balke‐Want, H., Keerthi, V., Cadiñanos-Garai, A., Fowler, C., Gkitsas-Long, N., Brown, A. K., Tunuguntla, R. H., Abou‐El‐Enein, M., & Feldman, S. A. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100375 · Cited by 75
“, Gaithersburg, MD), 4D-Nuclefector LV Unit (Lonza, Basel, Switzerland), CliniMACS Electroporator (Miltenyi Biotec), and the CTS Xenon (Thermo Fisher Scientific).(12,14,28,35,62,63) To increase the yield of edited cells, the development of cultivation vessels and closed systems that can handle larger volumes of starti…”
BackgroundHiltensperger, M., & Krackhardt, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121030 · Cited by 79
“Although PB transposition was also successful for the manufacturing of CAR-T cells and even showed an inclination to promote the generation of desired TSCM CAR-T cells (66, 67), a recent clinical trial observed the formation of CAR-T cell lymphoma in two out of ten patients (68, 69).”
BackgroundResultInfluentialEngineering strategies to safely drive CAR T-cells into the future
Rossi, M., & Breman, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1411393 · Cited by 68
Cost-effective strategies for CAR-T cell therapy manufacturing
Abdo, L., Batista-Silva, L. R., & Bonamino, M. H. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.200980 · Cited by 54
“33 However, two patients developed lymphoma originating from T cells modified with the PB-based tool.”
Madison, B., Patil, D. P., Richter, M., Li, X., Tong, M., Cranert, S. A., Wang, X., Martin, R. M., Xi, H., Tan, Y., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.06.003 · Cited by 61
“However, this event was likely not driven by classical insertional mutagenesis, as concluded by the authors themselves.(52,53) Rather, contributing factors likely included process-related parameters, such as DNA-damaging high-voltage electroporation conditions, and patient-specific exacerbating conditions, such as GVH…”
BackgroundOutcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
Bock, T., Colonne, C. K., Fiorenza, S., & Turtle, C. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-00992-5 · Cited by 53
“Rare occurrences of T cell lymphomas (TCL) in patients who have previously received treatment with approved CD19-targeted CAR T cells have been reported 96,98 , although transgene integration in the malignant T cells appears even less frequently 99,100 .”
Recent updates on allogeneic CAR-T cells in hematological malignancies
Mansoori, S., Noei, A., Maali, A., Seyed-Motahari, S. S., & Sharifzadeh, Z. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03479-y · Cited by 57
“The evaluations showed the high transgene copy number per cell and genetic changes such as point mutations and background genomic copy-number variations but no insertion into typical oncogenes [94].”
BackgroundCAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.
Harrison, S. J., Touzeau, C., Kint, N., Li, K., Nguyen, T., Mayeur-Rousse, C., Rahman, M., Bris, Y. L., Er, J., Eugène-Lamer, J., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2309728 · Cited by 54
Self-citationAdvancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
Kilgour, M. K., Bastin, D. J., Lee, S., Ardolino, M., McComb, S., & Visram, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166038 · Cited by 66
“There are at least two cases of T-cell lymphomas arising from CAR-modified cells, though it is important to note that both of these occurred in transposon modified cells, a process that can lead to many insertion events within a single cell (32).”
BackgroundWagner, D. L., Koehl, U., Chmielewski, M. M., Scheid, C., & Stripecke, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865424 · Cited by 65
Toxicities following CAR-T therapy for hematological malignancies
Hernani, R., Benzaquen, A. O., & Solano, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102479 · Cited by 55
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu, E., Luu, M., Alb, M., Anliker, B., Arcangeli, S., Bonini, C., Angelis, B. D., Choudhary, R., Espie, D., Galy, A. H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003486 · Cited by 66
Ruppel, K. E., Fricke, S., Koehl, U., & Schmiedel, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.822298 · Cited by 53
Wang, M., Krueger, J. B., Gilkey, A. K., Stelljes, E. M., Kluesner, M. G., Pomeroy, E. J., Skeate, J. G., Slipek, N. J., Lahr, W. S., Claudio Vázquez, P. N., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009560 · Cited by 45
“95 96 All of our CAR-NK products have copy numbers below 10, which is within the range that has been deemed safe and acceptable for advancing to evaluation in clinical trials.”
Automated, scaled, transposon-based production of CAR T cells
Lock, D., Monjezi, R., Brandes, C., Bates, S., Lennartz, S., Teppert, K., Gehrke, L., Karasakalidou-Seidt, R., Lukic, T., Schmeer, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005189 · Cited by 52
Qin, H., Zhou, Z., Shi, R., Mai, Y., Xu, Y., Fu, P., Cheng, G., Zhang, Z., Chen, W., Chen, Y., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01701-6 · Cited by 43
Golikova, E., Alshevskaya, A., Alrhmoun, S., Sivitskaya, N. A., & Sennikov, S. V. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05703-9 · Cited by 50
“The PiggyBac (PB) system was also successfully used to generate CAR-T cells [126], but later trials reported cases of CAR-T cell lymphoma [127, 128].”
MethodFeeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing
Gurney, M., Kundu, S., Pandey, S., & O'Dwyer, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802906 · Cited by 42
“This was highlighted by the incidence of product derived lymphomas in two patients treated with a Piggybac transposon-based CAR-T product which were recently reported, although the transposon system was not directly implicated in this occurrence, despite extensive investigation (67).”
BackgroundAggressive Lymphoma after CD19 CAR T-Cell Therapy
Kobbe, G., Brüggemann, M., Baermann, B., Wiegand, L., Trautmann, H., Yousefian, S., Libertini, S., Menssen, H. D., Maier, H. J., Ulrich, P. C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402730 · Cited by 60
Metanat, Y., Viktor, P., Amajd, A., Kaur, I., Hamed, A. M., Al-Abadi, N. K. A., Alwan, N. H., Chaitanya, M., Natrayan, L., Ghildiyal, P., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122683 · Cited by 49
Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
Dabiri, H., Kozani, P. S., Habibi‐Anbouhi, M., Godarzee, M. M., Haddadi, M. H., Basiri, M., Ziaei, V., Sadeghizadeh, M., & Saffar, E. H. (2023) · Biomarker Research · doi:10.1186/s40364-023-00509-1 · Cited by 45
“Moreover, as a high number of transgene copies and point mutations (not linked to the integration site) were documented, the transgene was not reported to be integrated into known oncogenes [11].”
BackgroundResultInfluentialOttaviano, G., & Qasim, W. (2025) · Leukemia · doi:10.1038/s41375-025-02585-8 · Cited by 45
“Extensive investigations were carried out to uncover possible mechanistic origins of these T cell malignancies [86].”
Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review
Moradi, V., Khodabandehloo, E., Alidadi, M., Omidkhoda, A., & Ahmadbeigi, N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1388475 · Cited by 42
Louie, R. H. Y., Cai, C., Samir, J., Singh, M., Deveson, I. W., Ferguson, J. M., Amos, T. G., McGuire, H. M., Gowrishankar, K., Adikari, T. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43656-7 · Cited by 38
“We analysed eight patients (Supplementary Table 1) with relapsed or refractory B-ALL or LBCL following HSCT who were treated with piggyBac-modi fi ed CD19 CAR T cells (second generation) within a clinical trial 28,29 .”
Self-citationDonor T cells for CAR T cell therapy
Tang, T. C. Y., Xu, N., Nordon, R. E., Haber, M., Micklethwaite, K. P., & Dolnikov, A. (2022) · Biomarker Research · doi:10.1186/s40364-022-00359-3 · Cited by 43
“Recent Phase I clinical trial (ACTRN12617001579381) data showed 9 out of 10 patients achieving complete remission after treatment with donor-derived piggyBac transposonbased CAR19T cells against r/r B-ALL or aggressive lymphoma post-HSCT; however, 2 patients developed malignant CAR19T cell-derived lymphoma that result…”
BackgroundSelf-citationGurney, M., O’Reilly, E., Corcoran, S., Brophy, S., Krawczyk, J., Otto, N., Hermanson, D., Childs, R. W., Szegezdi, É., & O'Dwyer, M. E. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.07.008 · Cited by 40
Alidadi, M., Barzgar, H., Zaman, M., Paevskaya, O. A., Metanat, Y., Khodabandehloo, E., & Moradi, V. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1491282 · Cited by 36
Current Non-Viral-Based Strategies to Manufacture CAR-T Cells
Gehrke, L., Gonçalves, V. D. R., Andrae, D., Raskó, T., Ho, P., Einsele, H., Hudecek, M., & Friedel, S. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413685 · Cited by 34
“Since there were some abnormalities but no obvious known trigger described, the cause of the transformation could not be clearly determined [62,63].”
Yao, P., Liu, Y., Huang, G., Hao, L., & Wang, R. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00583-7 · Cited by 33
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults
Lamble, A., Schultz, L., Nguyen, K., Hsieh, E. M., McNerney, K., Rouce, R., Gardner, R. A., Ghorashian, S., Shah, N. N., & Maude, S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013243 · Cited by 32
Buechner, J., Caruana, I., Künkele, A., Rives, S., Vettenranta, K. K., Bader, P., Peters, C., Baruchel, A., & Calkoen, F. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2021.784024 · Cited by 32
“Even though all three techniques are commonly used to generate autologous and allogeneic clinical-grade CAR products, recent evidence stresses a point of caution regarding the oncogenic potential of transposon systems (piggyBacs) with the first 2 cases of malignant lymphoma derived from CAR genetically modified T cell…”
BackgroundHosking, M. P., Shirinbak, S., Omilusik, K., Chandra, S., Kaneko, M., Gentile, A., Yamamoto, S., Shrestha, B., Grant, J., Boyett, M., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.05.007 · Cited by 30
“…for autologous or primary allogeneic T cells that are limited by uniformity of the edits, transgene size, safety concerns such as DNA breaks resulting in chromosome translocations, 46,47 clinical product yield, consistency, and homogeneity of the final drug product (reviewed in Dimitri et al. 48 ).”
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy
Hsieh, E. M., Myers, R. M., Yates, B., Annesley, C., John, S., Taraseviciute, A., Steinberg, S., Sheppard, J., Chung, P., Chen, L., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008093 · Cited by 28
Emerging T-cell lymphomas after CAR T-cell therapy
Braun, T., Kuschel, F., Reiche, K., Merz, M., & Herling, M. (2025) · Leukemia · doi:10.1038/s41375-025-02574-x · Cited by 27
“Exemplarily, molecular analyses of the fi nal CAR T-cell product were reported in only fi ve cases [7, 12, 13], with just one occurring outside a clinical trial [13].”
Court, A. C., Parra-Crisóstomo, E., Castro-Córdova, P., Abdo, L. D. M., Aragão, E. A. A., Lorca, R., Figueroa, F. E., Bonamino, M., & Khoury, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05627-4 · Cited by 28
“Clinical trials applying electroporation to generate CAR-T cells using non-viral vectors such as Sleeping Beauty or PiggyBac are underway [55–58].”
BackgroundEngineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
Schmidt, D., Ebrahimabadi, S., Gomes, K. R. D. S., Aguiar, G. D. M., Tirapelle, M. C., Silvestre, R. N., de Azevedo, J. T. C., Covas, D. T., & Picanço‐Castro, V. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac003 · Cited by 34
“However, this year two patients developed malignant lymphoma after treatment with CAR-Tcells genetically modified with a piggyBac vector [73].”
BackgroundIn vivo engineering of CAR-T cells: delivery strategies and clinical translation
Gao, Y., Hu, J., An, N., Wen, X., & Li, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-00899-y · Cited by 27
“It has enabled the generation of CNS-homing CAR-T cells [115] and allogeneic CAR-NK cells [116] in preclinical studies, with early-phase clinical trials (ACTRN12617001579381) underscoring its translational viability [117].”
The design of retroviral vectors used in the CAR‐T products, risk management, and future perspective
Yin, H., & Wei, X. (2025) · MedComm · doi:10.1002/mco2.70067 · Cited by 27
Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy
Dehghan, F., Metanat, Y., Askarizadeh, M., Ahmadi, E., & Moradi, V. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1511931 · Cited by 26
Yoshikawa, T., Ito, Y., Wu, Z., Kasuya, H., Nakashima, T., Okamoto, S., Amaishi, Y., Zhang, H., Li, Y., Matsukawa, T., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101526 · Cited by 26
“57 Although we did not observe aberrant expansion of G6/7R-M452L CAR-T cells after tumor eradication, careful evaluation of long-term T cell survival would be required in future clinical trials.”
Long‐term survivorship care after CAR‐T cell therapy
Puckrin, R., Jamani, K., & Jimenez-Zepeda, V. H. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14100 · Cited by 26
“96,97 To our knowledge, such occurrences of malignant transformation have not been described with other CAR-T cell products, but cases of clonal CAR-T cell expansion have been reported due to lentiviral integration into recipient BCL or TET2 genes.”
BackgroundBerg, P., Bakker, C., Sander, M., Lundstrøm, N. H., Erneholm, K., Musuamba-Tshinanu, F., Kholmanshikh, O., Nuffel, F. V., Müller, S., Ruppert-Seipp, G., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00586-x · Cited by 23
Gong, Y., Fei, P., Zhang, Y., Xu, Y., & Wei, J. (2025) · Advanced Science · doi:10.1002/advs.202501095 · Cited by 25
Liu, M., Zhang, L., Zhong, M., Long, Y.-H., Yang, W., Liu, T., Huang, X.-X., & Ma, X.-D. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00450-x · Cited by 23
“Compared with virus-transduced CAR T cells, very few clinical trials have applied CAR T cells prepared using PiggyBac system, and more attention needs to be paid on the safety of novel vector systems in future clinical trials [9].”
BackgroundiPS cell therapy 2.0: Preparing for next‐generation regenerative medicine
Hui, K. K., & Yamanaka, S. (2024) · BioEssays · doi:10.1002/bies.202400072 · Cited by 23
“[27,28] Thus, in addition to a desire for fine regulation of the cellular activities of iPSC-derived cells, the next iteration of iPSC-based therapies should inertsmallmolecule,AP1903,inducesthedimerizationofthismodified caspase-9, thus activating the intrinsic pathway of apoptosis to elicit…”
Zhou, Z.-K., Zhang, G., Xu, Y., Yang, S., Wang, J.-J., Li, Z.-R., Peng, F., & Lu, Q. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217083 · Cited by 21
Self-citationAnswering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
Banerjee, R. K., Poh, C., Hirayama, A. V. V., Gauthier, J., Cassaday, R. D., Shadman, M. S., Cowan, A. J., Till, B. G., Green, D. J., Kiem, H., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012336 · Cited by 22
“32 In the newly reported ASH abstract describing a T-cell lymphoma after cilta-cel, 4 workup revealed several acquired mutations (not due to CAR insertion) as well as a germline heterozygous JAK3 p.V722I variant previously associated with T-cell lymphoma-genesis.”
BackgroundGene knockout in cellular immunotherapy: Application and limitations
Zhang, X., Jin, X. K., Sun, R., Zhang, M., Lu, W., & Zhao, M. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215736 · Cited by 22
Current state of CAR-T cell therapies for solid tumors
Rosa, R. C. A., Liu, J., Lu, C., Abou‐El‐Enein, M., Murad, J. P., & Priceman, S. J. (2026) · Med · doi:10.1016/j.medj.2026.101028 · Cited by 21
Cheema, A. Y., Ali, H. M., Bibi, M., Aslam, M. F., Thiagarajan, P. S., Shahid, D., Munir, M., Najam, A., Raza, S., & Anwer, F. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.09.044 · Cited by 14
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
Melody, M., Epperla, N., Shouse, G., Romancik, J., Allen, P., Moyo, T. K., Kenkre, V., Ollila, T. A., Fitzgerald, L., Hess, B., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012573 · Cited by 19
“15,16 In light of the recent announcement by the FDA of reported cases of CAR-positive T-cell lymphomas after CAR T-cell therapy, we performed a large retrospective analysis examining the rates of SMNs in patients previously treated with anti-CD19 CAR T-cell therapy, with particular attention to…”
MethodSuematsu, M., Yagyu, S., Nagao, N., Kubota, S., Shimizu, Y., Tanaka, M., Nakazawa, Y., & Imamura, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.770132 · Cited by 21
CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future
Wu, H., Shafiei, F. S., Taghinejad, Z., Maleknia, M., Noormohamadi, H., Raoufi, A., Nouri, S., Servatian, N., & Samarkhazan, H. S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07151-5 · Cited by 20
“Further research is necessary to fully rule out this risk, even though follow-up studies in the field of CAR-T cells did not reveal any issues of this type [95].”
CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts
Berg, P., Ruppert‐Seipp, G., Müller, S., Maurer, G. D., Hartmann, J., Holtick, U., Buchholz, C. J., & Funk, M. B. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00183-2 · Cited by 20
“The development of a CAR-positive T-cell lymphoma was recently described following administration of CD19 CAR T cells generated using a nonviral piggyBac transposon system (Bishop et al, 2021; Micklethwaite et al, 2021).”
Challenges of Gene Editing Therapies for Genodermatoses
Brooks, I. R., Sheriff, A., Moran, D., Wang, J., & Jackow, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032298 · Cited by 23
“This has resulted in cases such as oncogenesis in patients treated with gene therapy for X-linked severe combined immunodeficiency (X-SCID) [27], and lymphoma has been reported in two patients after chimeric antigen receptor T-cell (CAR-T) therapy [28,29].”
BackgroundLussana, F., Magnani, C., Galimberti, S., Gritti, G., Gaipa, G., Belotti, D., Cabiati, B., Napolitano, S., Ferrari, S., Moretti, A., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01260-6 · Cited by 16
Clinical development of allogeneic chimeric antigen receptor αβ-T cells
Georgiadis, C., Preece, R., & Qasim, W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.040 · Cited by 17
“123,124 Allogeneic products should in theory not be at such a heightened risk of carrying predisposing changes, but as engineering steps become more sophisticated, with multiple changes being applied, diligent monitoring will be required.”
Chimeric antigen receptor T‐cells: Properties, production, and quality control
Ramesh, P., Hui, H. Y. L., Brownrigg, L., Fuller, K., & Erber, W. (2023) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14121 · Cited by 16
“A recent phase I clinical trial of anti-CD19 CAR T-cells manufactured using piggyBac vectors showed promise, with a complete response rate of 50% at 18 months.(39) However, 2 of 10 patients developed a CAR-expressing T-cell lymphoma.”
BackgroundBouziana, S. D., & Bouzianas, D. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179518 · Cited by 12
“The lymphomagenesis was related to high transgene insertion copy numbers, but it was thought that the widespread genomic copy number variations found within the genome of lymphoma cells was the dominant driver of carcinogenesis [30,82].”
BackgroundChabannon, C., Ruggeri, A., Montoto, S., van Biezen, A., van der Werf, S. M., Markslag, A., Sánchez‐Ortega, I., de la Cámara, R., Ljungman, P. T., Mohty, M., et al. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2024.101557 · Cited by 15
Russell, G. C., Hamzaoui, Y., Rho, D., Sutrave, G., Choi, J. S., Missan, D., Reckard, G. A., Gustafson, M. P., & Kim, G. B. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.03.484 · Cited by 15
Self-citationpiggyBac-transposon-mediated CAR-T cells for the treatment of hematological and solid malignancies
Yagyu, S., & Nakazawa, Y. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02319-9 · Cited by 15
“Nevertheless, in CAR-T cell-derived T-cell lymphoma cells, the incorporation of relatively high numbers of CAR transgenes (> 20 copies per cell), structural mutations, copy number changes, transcriptional read-through leading to overexpression of adjacent genes, and CAR transgenes in a region thought to be the cancer…”
BackgroundMethodAllogeneic Chimeric Antigen Receptor Therapy in Lymphoma
Khurana, A., & Lin, Y. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00920-6 · Cited by 17
A guide to CAR T cell therapies: development, current status and future prospects
Rafei, H., Upadhyay, R., & Sharma, P. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01322-1 · Cited by 14
Albalawi, Y. A. (2025) · Medical Oncology · doi:10.1007/s12032-025-02928-6 · Cited by 16
“While transposon is considered a suitable alternative for viral vectors at initiation, recently, CAR-T cell lymphoma has been reported in patients receiving piggyBac transposon-modified CAR-T cells [25].”
Shy, B. R., Vykunta, V. S., Ha, A. S., Roth, T. L., Talbot, A., Nguyen, D. N., Chen, Y. Y., Blaeschke, F., Vedova, S., Mamedov, M. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.02.458799 · Cited by 18
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them
Legato, L., Bisio, M., Fasano, F., Savelli, C. B., Secreto, C., Dellacasa, C. M., Botto, B., Busca, A., Cerrano, M., Freilone, R., et al. (2025) · Methods and Protocols · doi:10.3390/mps8050108 · Cited by 14
“However, concerns have been raised regarding potential insertional mutagenesis, especially with piggyBac, which has been associated with integration near oncogenes and rare cases of lymphomagenesis [118,119].”
Capolla, S., Rasool, M., Toffoli, G., & Bo, M. D. (2025) · Cancer Medicine · doi:10.1002/cam4.70726 · Cited by 13
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design
Gaimari, A., Lucia, A. D., Nicolini, F., Mazzotti, L., Maltoni, R., Rughi, G., Zurlo, M., Marchesini, M., Juan, M., Parras, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212201 · Cited by 16
Tuning CAR T-cell therapies for efficacy and reduced toxicity
Blud, D., Reyes, P. R., Perret, R., & Weinkove, R. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.07.003 · Cited by 14
Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy
Conti, A. G., Evans, A. C., von Linde, T., Deguit, C. D. T., Whiteside, S. K., Wesolowski, A. J., Imianowski, C. J., Yamashita-Kanemaru, Y., Dahmani, L., Chapman, J., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02389-z · Cited by 12
“Consistent with its role as a quiescence factor, recent reports show that BACH2 functions as a tumor suppressor gene in the context of CAR T cell-derived lymphoma 24,25 .”
Metadata
- Authors
- Micklethwaite, K. P., Gowrishankar, K., Gloss, B. S., Li, Z., Street, J. A., Moezzi, L., Mach, M. A., Sutrave, G., Clancy, L. E., Bishop, D. C., Louie, R. H. Y., Cai, C., Foox, J., MacKay, M., Sedlazeck, F. J., Blombery, P., Mason, C. E., Luciani, F., Gottlieb, D. J., & Blyth, E.
- Affiliations
- The University of Sydney (AU)
- Westmead Institute for Medical Research (AU)
- UNSW Sydney (AU)
- Weill Cornell Medicine (US)
- Baylor University (US)
- The Royal Melbourne Hospital (AU)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-10-21
- Volume
- 138
- Issue
- 16
- Pages
- 1391-1405
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC8532197
- OpenAlex
- W3163947612
- Cited by
- 226
- References
- 0
- Citations by year
- 2026: 32 · 2025: 54 · 2024: 63 · 2023: 30 · 2022: 33 · 2021: 14
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA249054, P01CA214274)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- piggyBac transposon, CD19 chimeric antigen receptor, retroperitoneal lymphoma, para-aortic lymph nodes, B-cell malignancies, transgene copy number, gene expression profiling, CAR T cell safety
- MeSH terms
- Aged, DNA Transposable Elements, Humans, Lymphoma, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Leukemia, B-Cell, Gene Expression Regulation, Neoplastic, Immunotherapy, Adoptive, Lymphoma, B-Cell, Clinical Trials, Phase I as Topic, Gene Transfer Techniques, Transgenes, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review